The 15 references in paper M. Ruda Ya., A. Syrkin I., E. Panchenko P., I. Yavelov S., O. Averkov V., R. Shahnovich M., A. Komarov L., М. РУДА Я., А. СЫРКИН Л., Е. ПАНЧЕНКО П., И. ЯВЕЛОВ С., О. АВЕРКОВ В., Р. ШАХНОВИЧ М., А. КОМАРОВ Л. (2015) “РЕЗЮМЕ СОВЕТА ЭКСПЕРТОВ, ПОСВЯЩЕННОГО ОБСУЖДЕНИЮ ЗНАЧЕНИЯ ПРЕПАРАТА РИВАРОКСАБАН ВЛЕЧЕНИИ БОЛЬНЫХ, ПЕРЕЖИВШИХ ОСТРЫЙ КОРОНАРНЫЙ СИНДРОМ // SUMMARY OF CONCLUSIONS FROM A CONSENSUS PANEL OF EXPERTS ON THE IMPORTANCE OF RIVAROXABAN IN THE MANAGEMENT OF PATIENTS RECOVERING FROM ACUTE CORONARY SYNDROME” / spz:neicon:aterotromboz:y:2015:i:2:p:86-94

1
Yusuf S et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndroms without ST segment elevation. N Engl J Med, 2001. 345(7): 494–502.
(check this in PDF content)
2
Wallentine L et al. Ticagrelor versus clopidogrel in patients with acure coronary syndromes. N Engl J Med, 2009. 361(11): 1045–1057.
(check this in PDF content)
3
Stone GW et al. A prospective Natural-History Study of Coronary atherosclerosis. N Engl J Med, 2011. 364: 226–235.
(check this in PDF content)
4
Merlini et al. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation, 1994. 90(1): 61–68.
(check this in PDF content)
5
Husted SE et al. Benefits of extended treatment with dalteparin in patients with unstable coronary artery disease eligible for revascularization. Eur heart J,2002. 23(15): 1213–1218.
(check this in PDF content)
6
Rothberg MB et al. Warfarin plus aspirin after MI or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med,2005. 143(4): 241–250.
(check this in PDF content)
7
Hansen ML et al. Risk of bleeding with single, dual, or triple therapy witn warfarin, aspirin, and clopidogrel inpatients with atrial fibrillation. Arch Intern Med, 2010. (16): 1433–1441.
(check this in PDF content)
8
Mega J et al. Rivaroxaban versus placebo in patients with acute coronary syndromes (ATLAS ACS-TIMI46): a randomized, double-blined, phase II trial. Lancet, 2009. 374: 29–38.
(check this in PDF content)
9
Mega J et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med,2012. 366: 9–11.
(check this in PDF content)
10
Mega J et al. Comparison of the efficacy and safety of two Rivaroxaban doses in acute coronary syndrome (from ATLAS ACS-TIMI 51). Am J Cardiol, 2013. 112: 472–478.
(check this in PDF content)
11
Mega J et al. Rivaroxaban in patients stabilized after a ST-segment elevation myocardial infarction. J Am Coll Cardiol, 2013. 61: 1853–9.
(check this in PDF content)
12
Gibson M et al. Reduction of stent thrombosis in patients with acute coronary syndromes treated with rivaroxaban in ATLAS-ACS 2 TIMI 51. J Am Coll Cardiol, 2013. 62: 286–290.
(check this in PDF content)
13
ESC Guidelines for the management of acute myocardial infarction in patients presenting with STsegment elevation. Eur Heart J, 2012. 33: 2569–2619.
(check this in PDF content)
14
2014 ESC/EACTS Guidelines on myocardial revascularization. doi:10.1093eurheartj/ehu278.
(check this in PDF content)
15
2015 ESC Guigelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. doi:10.1093/eurheartj/ehv320. ральными антикоагулянтами возможно назна-
(check this in PDF content)